Emil "Tom" Frei III was an American physician and oncologist. He was the former director and former physician-in-chief of the Dana–Farber Cancer Institute in Boston, Massachusetts. He was also the Richard and Susan Smith Distinguished Professor of Medicine at Harvard Medical School.
George P. Canellos is an American oncologist and cancer researcher. His research career spans many decades, as well as several areas of therapeutic agents for the treatment of malignant diseases. He is perhaps most known for his work with Vincent T. DeVita in which he developed the combination chemotherapy CMF, which was one of the first combination therapies for breast cancer. The two also collaborated to create the MOPP regimen for Hodgkin's lymphoma.
The Society for Immunotherapy of Cancer (SITC), previously known as the International Society for Biological Therapy of Cancer (iSBTc), is a professional society of scientists, academicians, researchers, clinicians, government representatives, and industry leaders from around the world dedicated to improving outcomes in patients with cancer by advancing the science and application of cancer immunotherapy. Currently, SITC has more than 2,400 members, representing 22 medical specialties from 42 countries around the world, who are engaged in the research and treatment of cancer.
Oncology is a branch of medicine that deals with the study, treatment, diagnosis and prevention of tumors. A medical professional who practices oncology is an oncologist. The name's etymological origin is the Greek word ὄγκος (ónkos), meaning "tumor", "volume" or "mass". Oncology is concerned with:
William K. Oh, is an American medical oncologist, academic and industry leader and expert in the management of genitourinary malignancies, including prostate, renal, bladder and testicular cancers.
The Lustgarten Foundation is a 501(c)(3) non-profit organization foundation dedicated to advancing the research related to the diagnosis, treatment, cure and prevention of pancreatic cancer while raising public awareness and providing support to patients and their families. The Foundation is the largest private funder of pancreatic cancer research in the world. Based in Woodbury, Nassau County, New York, the Foundation's mission is to cure pancreatic cancer by funding scientific and clinical research related to the diagnosis, treatment, and prevention of pancreatic cancer; providing research information and clinical support services to patients, caregivers and individuals at high risk; and increasing public awareness and hope for those dealing with this disease. Increasing funding and support of research into the biological mechanisms and clinical strategies related to the prevention, diagnosis, and treatment of pancreatic cancer; Facilitating and enhancing the dialogue among members of the medical and scientific communities about basic and clinical research efforts that relate to pancreatic cancer; Heightening public awareness of pancreatic cancer diagnosis, treatment, and prevention and providing informational support for pancreatic cancer patients, their families, and friends.
Eric P. Winer is a medical oncologist and clinical researcher specializing in breast cancer. He is director of Yale Cancer Center and physician-in-chief of Smilow Cancer Hospital at Yale New Haven Health, effective February 1, 2022. He also is Deputy Dean for Cancer Programs at the Yale School of Medicine. From 1997 to 2021, he was the Chief of the Breast Oncology Program at Dana–Farber Cancer Institute in Boston, Massachusetts. Beginning in 2013, he held a range of institutional roles at Dana-Farber, including Chief of Clinical Development, the Thompson Chair in Breast Cancer Research and Director of the Dana-Farber/Harvard SPORE in Breast Cancer. He also served as a Professor of Medicine at Harvard Medical School. He was president of the American Society of Clinical Oncology (ASCO) 2022-2023 and became Chair of the Board in mid-June 2023. His career has been focused on breast cancer treatment and research.
William G. Kaelin Jr. is an American Nobel laureate physician-scientist. He is a professor of medicine at Harvard University and the Dana–Farber Cancer Institute. His laboratory studies tumor suppressor proteins. In 2016, Kaelin received the Albert Lasker Award for Basic Medical Research and the AACR Princess Takamatsu Award. He also won the Nobel Prize in Physiology or Medicine in 2019 along with Peter J. Ratcliffe and Gregg L. Semenza.
Kenneth C. Anderson is an American hematologist-oncologist and cancer researcher who is primarily known for advances in the treatment of multiple myeloma. He directs the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center at Dana–Farber Cancer Institute and is the Kraft Family Professor of Medicine and Vice Chair of the Joint Program in Transfusion Medicine at Harvard Medical School.
Daniel D. Von Hoff is the physician in chief and director of translational research at Translational Genomics Research Institute (TGen), and current Virginia G. Piper Distinguished Chair for Innovative Cancer Research at HonorHealth Clinical Research Institute. He is also a professor of medicine at the Mayo Clinic and medical director of research as well as chief scientific officer at US Oncology. He is most notable for his work in targeted therapies for the treatment of cancer. He led the development of gemcitabine, and has several drugs in development.
Mary-Ellen Taplin, is a research oncologist at Dana Farber Cancer Institute and Brigham and Women's Hospital in Harvard's Longwood Medical and Academic Area.
Elizabeth M. Jaffee is an American oncologist specializing in pancreatic cancer and immunotherapy.
Jeffrey Drebin is a surgeon and scientist. He serves as the Department of Surgery Chair at Memorial Sloan Kettering.
Edith Peterson Mitchell is a retired Brigadier general of the United States Air Force and an oncologist. She is clinical professor of medicine and medical oncology at Thomas Jefferson University. In 2015, she became the president of the National Medical Association.
Philip W. Kantoff is a medical oncologist. He is the chairman and chief executive officer (CEO) of Convergent Therapeutics. He served as the Chairman of Medicine at Memorial Sloan Kettering Cancer Center between 2015 and 2021. He is best known for his contributions to the impact of DNA abnormalities in prostate cancer and the discovery of therapies for metastatic hormone-sensitive prostate cancer.
Levi A. Garraway is an American oncologist. His research team was among the first to adapt genomics technologies to enable scalable, high-throughput clinical approaches to cancer gene mutation profiling. As a result, he was inducted into the American Society for Clinical Investigation, American Association for Cancer Research, and National Academy of Medicine.
Daphne Adele Haas-Kogan is an American radiation oncologist. She is the Willem and Corrie Hees Family Professor of Radiation Oncology at Harvard Medical School.
Nilofer Saba Azad is an American oncologist and physician-scientist specialized in gastrointestinal, colorectal, cholangiocarcinoma, and pancreaticobiliary cancers. She is a professor at the Johns Hopkins School of Medicine and oversees clinical trials at the Sidney Kimmel Comprehensive Cancer Center.
Monica Bertagnolli is an American surgical oncologist and the 16th director of the National Cancer Institute. Previously, she worked at Brigham and Women's Hospital and Dana–Farber Cancer Institute and was the Richard E. Wilson Professor of Surgery at Harvard Medical School. She has advocated for inclusion of rural communities in clinical studies and served as Chair of the Alliance for Clinical Trials in Oncology until her appointment to lead NCI. Bertagnolli specializes in the treatment of tumors from gastrointestinal diseases and soft tissue sarcomas. She is the former President of the American Society of Clinical Oncology and was elected Fellow of the National Academy of Medicine in 2021. In 2023, President Biden nominated Bertagnolli to serve as the director of the National Institutes of Health. If confirmed, she would be the second woman director of the NIH.
Soma Sengupta, MD, PhD, FRCP is a British-American physician-scientist and holds the Harold C. Schott Endowed Chair of Molecular Therapeutics at the University of Cincinnati College of Medicine. She is a specialty board certified neuro-oncologist board certified Neurologist as well as fellowship-trained in Integrative Medicine. She is a full-time faculty member of the Department of Neurology and Rehabilitation Medicine at the University of Cincinnati and on the Medical Staff at Cincinnati Children's Hospital Medical Center.
